Cothera Bioscience announced the closing of nearly $30 million in its Series B financing. This funding was led by Tsing Song Capital, with participation from CMB International Capital, Sherpa Healthcare Partners, New World Investment, Longshine Investment, Harbinger Venture, as well as existing shareholders Legend Capital and Legend Star. The funds will be primarily used to accelerate the global clinical development of the company's multiple tumor-targeting innovative drugs.

CEC Capital Group served as the exclusive financial advisor for Cothera Bioscience in this transaction.

Cothera Bioscience was founded by the core members of the CrownBio founding team and is focused on innovative tumor-targeted drug development. Its self-developed i-CR? technology platform combines conditional reprogramming (CR) primary tumor cell culture technology and high-content drug screening system. This allows efficient and unbiased amplification of patient-derived tumor cells in vitro, preserving the heterogeneity of the patient's tumor. The platform also utilizes high-content drug screening system to efficiently screen drugs using patient-derived tumor cells in vitro, making it more suitable for personalized drug screening and new drug development for clinical patients. Through collaborations with top domestic oncology medical centers, Cothera Bioscience has conducted several prospective comparative clinical trials, which have initially demonstrated that the i-CR? system can effectively predict the actual clinical response to drugs, thus greatly improving the efficiency and clinical success rate of anti-tumor drug development.